Treatment of lung cancers with the epidermal growth factor receptor (EGFR) inhibitor, gefitinib (Iressa), is promising in patients carrying point mutations in the EGFR kinase domain (Couzin, 2002; Herbst et al, 2004). The gene discussed is EGFR; the disease is lung cancer.